Sometimes the best way to fix a mistake is to double down on it—and that is just what DexCom is doing with its continuous glucose monitors for diabetes patients. It’s a decision that should pay off ...
DexCom shares took a slight tumble after earnings were announced Thursday evening off of strong results. Guidance for the year was upgraded due to growing demand and FDA clearance for the Apple Watch ...
DexCom received FDA approval for its continuous glucose monitoring product, Stelo, to be available over the counter, making it the first OTC CGM product ever. The company has demonstrated robust ...
Predictions of a sales-growth slowdown sent DexCom stock tumbling this summer. Management predicted third-quarter sales would rise by just 1% to 3% year over year. Two of DexCom's top competitors ...
DexCom's growth rate has been declining over multiple periods. The company expects as little as 1% organic growth for the current quarter. Investors may see this as proof that GLP-1 drugs are ...
DexCom (DXCM) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock ...
On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4%, while ...
DexCom (NASDAQ:DXCM) has been analyzed by 9 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results